CD3:B7H3 bispecific T cell engager

CD3:B7H3 bispecific T cell engager is a class of bispecific antibodies designed to redirect T cells to eliminate B7-H3 (CD276)-expressing tumor cells. These molecules typically feature two binding domains: one targeting CD3, a subunit of the T-cell receptor complex on T lymphocytes, and another targeting B7-H3, an immune checkpoint protein overexpressed in various solid tumors, including glioblastoma, medulloblastoma, and sarcomas. By simultaneously binding to both targets, the engager physically bridges T cells and tumor cells, triggering T-cell activation, proliferation, and directed cytotoxic activity against the cancer cells. Multiple candidates utilizing this mechanism, such as MacroGenics' obrindatamab (MGD009) and Takeda's TAK-280, have been investigated in preclinical and clinical settings.

Other names

B7-H3 x CD3 bispecific T-cell engagerB-7-H3 x CD3 bispecific T-cell engagerB 7-H3 x CD3 bispecific T-cell engagerB7-H3/CD3 bispecific antibodyB7H3 x CD3 BiTEB-7H3 x CD3 BiTEB 7H3 x CD3 BiTEB7H3 x CD3 bispecific T-cell engagerB-7H3 x CD3 bispecific T-cell engagerB 7H3 x CD3 bispecific T-cell engagerCD3 x B7-H3 bispecific T-cell engagerCD-3 x B7-H3 bispecific T-cell engagerCD 3 x B7-H3 bispecific T-cell engagerCD3 x B7H3 BiTECD-3 x B7H3 BiTECD 3 x B7H3 BiTECD3:B7H3 BTECD3:B7H3 bispecific T-cell engager